Who are UFT (uracil, tegafur)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xeloda, Fudr, Folic Acid, Phthalin, XELODA [capecitabine], Capecitabine (Xeloda®).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/uft-uracil-tegafur.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

UFT (uracil, tegafur) — Competitive Intelligence Brief

UFT (uracil, tegafur) (UFT (uracil, tegafur)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fluoropyrimidine antimetabolite. Area: Oncology.

phase 3 Fluoropyrimidine antimetabolite Thymidylate synthase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

UFT (uracil, tegafur) (UFT (uracil, tegafur)) — Taiho Pharmaceutical Co., Ltd.. UFT is a combination of uracil and tegafur that inhibits thymidylate synthase to block DNA synthesis and induce cancer cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
UFT (uracil, tegafur) TARGET	UFT (uracil, tegafur)	Taiho Pharmaceutical Co., Ltd.	phase 3	Fluoropyrimidine antimetabolite	Thymidylate synthase
Xeloda	capecitabine	Cheplapharm	marketed	Nucleoside Metabolic Inhibitor [EPC]	Thymidylate synthase	1998-01-01
Fudr	FLOXURIDINE		marketed	Antimetabolite [EPC]	Thymidylate synthase	1970-01-01
Folic Acid	FOLIC ACID	Pfizer	marketed	Vitamin C [EPC]	Thymidylate synthase	1946-01-01
Phthalin	PHENOLPHTHALEIN		marketed	phenolphthalein	Thymidylate synthase, Thymidylate synthase
XELODA [capecitabine]	XELODA [capecitabine]	Hoffmann-La Roche	marketed	Fluoropyrimidine antimetabolite	Thymidylate synthase
Capecitabine (Xeloda®)	Capecitabine (Xeloda®)	National Cancer Center, Korea	marketed	Fluoropyrimidine antimetabolite	Thymidylate synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fluoropyrimidine antimetabolite class)

Federation Francophone de Cancerologie Digestive · 2 drugs in this class
National Cancer Center, Korea · 2 drugs in this class
Hoffmann-La Roche · 1 drug in this class
Japan Clinical Oncology Group · 1 drug in this class
Jiangxi Provincial Cancer Hospital · 1 drug in this class
Peter MacCallum Cancer Centre, Australia · 1 drug in this class
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 1 drug in this class
Taiho Pharmaceutical Co., Ltd. · 1 drug in this class
The First Affiliated Hospital of Henan University of Science and Technology · 1 drug in this class
UNICANCER · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). UFT (uracil, tegafur) — Competitive Intelligence Brief. https://druglandscape.com/ci/uft-uracil-tegafur. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab